HomeFile

File

TCT 2025 | PARTNER 3 Trial 7-Year Outcomes: TAVR vs SAVR in Low-Risk Patients

The randomized PARTNER 3, which initially showed TAVR superiority when using the SAPIEN 3 valve over SAVR...

TCT 2025 | VICTORY Trial: super-high-pressure NC balloon vs. IVL in severely calcified coronary lesions

Recent studies such as ECLIPSE have demonstrated the safety of non-compliant (NC) balloons compared with orbital atherectomy,...

TCT 2025 | ShortCUT Trial: intravascular lithotripsy vs. cutting balloon in calcified coronary lesions

Coronary calcification is a major determinant of PCI complexity and failure. Balloon-based plaque-modifying devices —such as cutting...

TCT 2025 | SELUTION4ISR: sirolimus-eluting balloon for in-stent restenosis

In-stent restenosis (ISR) continues to be a relevant clinical challenge in contemporary PCI practice. In the DES...

TCT 2025 | SELUTION DeNovo: sirolimus-eluting balloon vs. stent in de novo coronary lesions

The use of drug-eluting stents (DES) remains the standard strategy in most percutaneous coronary intervention (PCI) procedures....

HELP-PCI: A Fleeting Advantage of Early Heparin in ST-Elevation Myocardial Infarction?

In ST-elevation myocardial infarction (STEMI), immediate reperfusion through primary percutaneous coronary intervention (pPCI) remains the treatment of...

IVUS – Measured Optimal Minimal Stent Area in Left Main Crossover Stenting

The current guidelines recommend the use of intravascular ultrasound (IVUS) during left main stenting to optimized PCI...

Impact of Amyloidosis on Outcomes After TAVI

Cardiac amyloidosis (CA) is a systemic and progressive disease characterized by the accumulation of misfolded proteins in...